|
|||||
|
|
Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance |
|
| Authors: | Mochizuki Toshio Muto Satoru Miyake Masateru Tanaka Toshiki Wang Wenchyi |
| Institution: | 1.Department of Nephrology, Tokyo Women’s Medical University, Tokyo, Japan ;2.Clinical Research Division for Polycystic Kidney Disease, Department of Nephrology, Tokyo Women’s Medical University, Tokyo, Japan ;3.Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan ;4.Department of Advanced Informatics for Genetic Disease, Graduate School of Medicine, Juntendo University, Tokyo, Japan ;5.Department of Pharmacovigilance, Otsuka Pharmaceutical Co., Ltd, 3-2-27 Otedori, Chuo-ku, Osaka, 540-0021, Japan ;6.Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd, 3-2-27 Otedori, Chuo-ku, Osaka, 540-0021, Japan ;7.Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, USA ; |
| Abstract: | Clinical and Experimental Nephrology - Tolvaptan is a vasopressin type 2 receptor antagonist and has been used to treat autosomal dominant polycystic kidney disease (ADPKD) since 2014. There has... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |